🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

44 results for “AXIM” Clear

  1. A First-in-human study to learn how safe the study drug BAY2965501 is, find the best dose (single drug & combination), how it affects the body, what maximum amount can be given, how it moves into, through and out of the body, how it acts on different tumors in participants with advanced solid tumors

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  2. A first-in-human study to learn how safe the study treatment BAY2862789 is, to find the best dose, how it affects the body, what maximum amount can be given, how it moves into, through and out of the body, and how it acts on different tumors in participants with advanced solid tumors

    Bayer AG

    Advanced solid tumors, Non-small cell lung cancer

    phase 1 other active

    1 trial

  3. A study to learn how safe the study drug BAY 2416964 (AhR inhibitor) in combination with the treatment pembrolizumab is, how this combination affects the body, the maximum amount that can be given, how it moves into, through and out of the body and its action against advanced solid cancers in adults

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  4. An open-label dose escalation study to estimate maximum tolerated dose (MTD), identify dose-limiting toxicities (DLTs) and study pharmacokinetics following a single dose of intracranially administered temozolomide-based SI-053 as an add-on to the current standard of care (SoC), in adult patients with newly diagnosed glioblastoma (GBM).

    Pharma Mar S.A.

    Glioblastoma

    phase 1 other active

    1 trial

  5. Chewing Gum

    AXIM BIOTECHNOLOGIES, INC.

    THC

    phase 1 small molecule active

    1 trial

  6. ONC206 Powder

    AXIM BIOTECHNOLOGIES, INC.

    Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

    phase 1 small molecule active

    1 trial

  7. PHASE I STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE FOR TRICHOSTATIN A IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

    Pharma Mar S.A.

    relapsed/refractory hematologic malignancies

    phase 1 other active

    1 trial

  8. Study to evaluate the safety, tolerability, maximum tolerated dose and clinical activity of TNB-383B when given to patients with multiple myeloma

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or refractory multiple myeloma

    phase 1 other active

    1 trial

  9. Vyxeos Liposomal 44 mg/100 mg powder for concentrate for solution for infusion., Evoltra 1 mg/ml concentrate for solution for infusion

    AXIM BIOTECHNOLOGIES, INC.

    AML

    phase 1 small molecule active

    1 trial

  10. WT1-loaded CBDC Vaccine

    AXIM BIOTECHNOLOGIES, INC.

    AML: Acute Myeloid Leukemia/ cancer of blood and bone marrow

    phase 1 small molecule active

    1 trial

  11. Ziftomenib, Ziftomenib, Cytarabine 20 mg/ml Solution for Injection/Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Ziftomenib, Cytarabine 20 mg/ml Solution for Injection/Infusion, Solu-Cortef Powder for Solution for Injection or Infusion 100 mg

    AXIM BIOTECHNOLOGIES, INC.

    Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Acute Lymphocytic Leukemia

    phase 1 small molecule active

    1 trial

  12. AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CEFEPIME , CEFOTAXIME, SPIRAMYCIN , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

    Pari Pharma GmbH

    EA-COPD (with mechanical ventilation, invasive or non-invasive, or high-flow nasal oxygen therapy).

    approved small molecule active

    1 trial

  13. Rifaximin

    United Therapeutics Europe Ltd

    Clostridium Difficile Infection

    approved small molecule completed

    1 trial

  14. Rifaximin

    United Therapeutics Europe Ltd

    Nonalcoholic Fatty Liver Disease

    approved small molecule terminated

    1 trial

  15. Rifaximin

    COLLEGIUM PHARMACEUTICAL, INC

    ACS - Acute Coronary Syndrome

    approved small molecule active

    1 trial

  16. Rifaximin

    First Tracks Biotherapeutics

    IBS - Irritable Bowel Syndrome

    approved small molecule active

    1 trial

  17. Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum

    United Therapeutics Europe Ltd

    Frostbite

    approved small molecule active

    1 trial

  18. Rifaximin

    United Therapeutics Europe Ltd

    Travelers' Diarrhea

    small molecule completed

    1 trial

  19. Rifaximin

    United Therapeutics Europe Ltd

    Tropical Enteropathy

    small molecule completed

    1 trial

  20. Rifaximin

    First Tracks Biotherapeutics

    Bacterial Overgrowth Syndrome Small Bowel

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources